Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players

Drugs

Volumn 75, Issue 18, 2015, Pages 2097-2117

  Lee, Young R ^a   McMahan, Danni ^a   McCall, Catherine ^a   Perry, Gregory K ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Hendrick Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AVIBACTAM PLUS CEFTAZIDIME; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; DELAFLOXACIN; DORIPENEM; ERAVACYCLINE; ERTAPENEM; FINAFLOXACIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PLAZOMICIN; RELEBACTAM; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; TIMENTIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; COMMUNITY ACQUIRED INFECTION; DISEASE SEVERITY; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INFECTION CONTROL; INFECTION RISK; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; TREATMENT DURATION; COMBINATION DRUG THERAPY; DRUG DESIGN; INTRAABDOMINAL INFECTIONS; MICROBIOLOGY;

ANTI-INFECTIVE AGENTS; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HUMANS; INTRAABDOMINAL INFECTIONS; PRACTICE GUIDELINES AS TOPIC;

EID: 84949107864     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0506-7     Document Type: Article

References (79)

1. Shirah GR, O'Neill PJ. Intra-abdominal infections. Surg Clin North Am. 2014;94(6):1319-33. doi: 10.1016/j.suc.2014.08.005.
2. Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs. 2012;72(6):e17-32. doi: 10.2165/11599800-000000000-00000.
3. Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A. National Hospital Discharge survey: 2007 summary. Natl Health Stat Report. 2010;29:1-20, 24.
4. Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World J Emerg Surg. 2014;9:37. doi: 10.1186/1749-7922-9-37.
5. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-64. doi: 10.1086/649554.
6. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785-96. doi: 10.1016/s1473-3099(13)70190-7.
7. Watkins RR, Bonomo RA. Increasing prevalence of carbapenem-resistant Enterobacteriaceae and strategies to avert a looming crisis. Expert Rev Anti Infect Ther. 2013;11(6):543-5. doi: 10.1586/eri.13.46.
8. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt). 2010;11(1):79-109. doi: 10.1089/sur.2009.9930.
9. Chow AW, Evans GA, Nathens AB, Ball CG, Hansen G, Harding GK, et al. Canadian practice guidelines for surgical intra-abdominal infections. Can J Infect Dis Med Microbiol. 2010;21(1):11-37.
10. Sartelli M, Viale P, Catena F, Ansaloni L, Moore E, Malangoni M, et al. 2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2013;8(1):3. doi: 10.1186/1749-7922-8-3.
11. Powell LL, Wilson SE. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg Infect (Larchmt). 2000;1(1):57-63. doi: 10.1089/109629600321308.
12. Moellering RC Jr, Swartz MN. Drug therapy: the newer cephalosporins. N Engl J Med. 1976;294(1):24-8. doi: 10.1056/nejm197601012940106.
13. Brogden RN, Spencer CM. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections. Drugs. 1997;53(3):483-510.
14. Brogden RN, Heel RC, Speight TM, Avery GS. Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979;17(4):233-66.
15. Brogden RN, Heel RC, Speight TM, Avery GS. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979;17(1):1-37.
16. Richards DM, Brogden RN. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985;29(2):105-61.
17. Todd PA, Benfield P. Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1990;39(2):264-307.
18. Daniel KP, Krop LC. Piperacillin-tazobactam: a new beta-lactam-beta-lactamase inhibitor combination. Pharmacotherapy. 1996;16(2):149-62.
19. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027-52.
20. Chow KM, Szeto CC, Hui AC, Wong TY, Li PK. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy. 2003;23(3):369-73.
21. Tanaka A, Takechi K, Watanabe S, Tanaka M, Suemaru K, Araki H. Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem. Int J Clin Pharm. 2013;35(5):683-7. doi: 10.1007/s11096-013-9799-3.
22. Perry CM, Brogden RN. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1996;52(1):125-58.
23. Brogden RN, Ward A. Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration. Drugs. 1988;35(6):604-45.
24. Bickford CL, Spencer AP. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy. 2005;25(10):1389-95. doi: 10.1592/phco.2005.25.10.1389.
25. Monte SV, Prescott WA, Johnson KK, Kuhman L, Paladino JA. Safety of ceftriaxone sodium at extremes of age. Expert Opin Drug Saf. 2008;7(5):515-23. doi: 10.1517/14740338.7.5.515.
26. Nadler EP, Reblock KK, Ford HR, Gaines BA. Monotherapy versus multi-drug therapy for the treatment of perforated appendicitis in children. Surg Infect (Larchmt). 2003;4(4):327-33. doi: 10.1089/109629603322761382.
27. St Peter SD, Tsao K, Spilde TL, Holcomb GW III, Sharp SW, Murphy JP, et al. Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial. J Pediatr Surg. 2008;43(6):981-5. doi: 10.1016/j.jpedsurg.2008.02.018.
28. Klion AD, Kallsen J, Cowl CT, Nauseef WM. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med. 1994;154(5):586-9.
29. Okamoto MP, Nakahiro RK, Chin A, Bedikian A. Cefepime clinical pharmacokinetics. Clin Pharmacokinet. 1993;25(2):88-102. doi: 10.2165/00003088-199325020-00002.
30. Endimiani A, Perez F, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther. 2008;6(6):805-24. doi: 10.1586/14787210.6.6.805.
31. Lam S, Gomolin IH. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy. 2006;26(8):1169-74. doi: 10.1592/phco.26.8.1169.
32. Gangireddy VG, Mitchell LC, Coleman T. Cefepime neurotoxicity despite renal adjusted dosing. Scand J Infect Dis. 2011;43(10):827-9. doi: 10.3109/00365548.2011.581308.
33. Ball P. The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections. Int J Antimicrob Agents. 2007;30(Suppl 2):S113-7. doi: 10.1016/j.ijantimicag.2007.07.037.
34. Brogden RN, Heel RC, Speight TM, Avery GS. Ticarcillin: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1980;20(5):325-52.
35. Fass RJ, Prior RB. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother. 1989;33(8):1268-74.
36. Reed MD. A reassessment of ticarcillin/clavulanic acid dose recommendations for infants, children and adults. Pediatr Infect Dis J. 1998;17(12):1195-9.
37. Chahine EB, Ferrill MJ, Poulakos MN. Doripenem: a new carbapenem antibiotic. Am J Health Syst Pharm. 2010;67(23):2015-24. doi: 10.2146/ajhp090672.
38. Zhanel GG, Walkty A, Vercaigne L, Karlowsky JA, Embil J, Gin AS, et al. The new fluoroquinolones: a critical review. Can J Infect Dis. 1999;10(3):207-38.
39. Cheadle W, Lee JT, Napolitano LM, Nichols RL. Clinical update on the use of moxifloxacin in the treatment of community-acquired complicated intraabdominal infections. Surg Infect (Larchmt). 2010;11(5):487-94. doi: 10.1089/sur.2009.062.
40. Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother. 2008;9(10):1755-72. doi: 10.1517/14656566.9.10.1755.
41. Butler MS, Hansford KA, Blaskovich MA, Halai R, Cooper MA. Glycopeptide antibiotics: back to the future. J Antibiot (Tokyo). 2014;67(9):631-44. doi: 10.1038/ja.2014.111.
42. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther. 2006;28(8):1079-106. doi: 10.1016/j.clinthera.2006.08.011.
43. Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75(4):331-6. doi: 10.1016/j.diagmicrobio.2012.12.004.
44. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54(5):679-708.
45. Lofmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. 2010;50(Suppl 1):S16-23. doi: 10.1086/647939.
46. Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet. 1992;23(5):328-64. doi: 10.2165/00003088-199223050-00002.
47. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagace-Wiens PR, et al. Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs. 2013;73(2):159-77. doi: 10.1007/s40265-013-0013-7.
48. Lagace-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid. 2014;9:13-25. doi: 10.2147/ce.s40698.
49. Tarral A, Merdjan H. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Clin Ther. 2015;37(4):877-86. doi: 10.1016/j.clinthera.2015.01.009.
50. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56(12):6137-46. doi: 10.1128/aac.00851-12.
51. Eckmann C, Solomkin J. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections. Expert Opin Pharmacother. 2015;16(2):271-80. doi: 10.1517/14656566.2015.994504.
52. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012;56(6):3086-91. doi: 10.1128/aac.06349-11.
53. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 2011;55(5):2390-4. doi: 10.1128/aac.01737-10.
54. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US Hospitals (2011-2012). Antimicrob Agents Chemother. 2013;57(12):6305-10. doi: 10.1128/aac.01802-13.
55. Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010;65(9):1972-4. doi: 10.1093/jac/dkq248.
56. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74(1):31-51. doi: 10.1007/s40265-013-0168-2.
57. Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig WA, Andes D. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2014;58(10):6311-4. doi: 10.1128/aac.03572-14.
58. Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2014;58(2):1218-23. doi: 10.1128/aac.02253-13.
59. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother. 2013;68(5):1183-92. doi: 10.1093/jac/dks523.
60. Mazuski JE, Gasnik L, Armstrong J, Broadhurst H, Stone G, Rank D et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection - results from a phase III program. In: 25th European Congress of Clinical Microbiology and Infectious Diseases; April 27, 2015; Copenhagen, Denmark.
61. Lucasti C, Hershberger E, Miller B, Yankelev S, Steenbergen J, Friedland I, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58(9):5350-7. doi: 10.1128/aac.00049-14.
62. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60(10):1462-71. doi: 10.1093/cid/civ097.
63. Red Book Online [online database]. Greenwood Village, CO: Truven Health Analytics; 2015.
64. Avycaz [package insert]. Verona, Italy: GlaxoSmithKline Manufacturing S.p.A.; 2015.
65. Zerbaxa [package insert]. Syracuse, NY: Steri-Pharma, LLC; 2015.
66. Antibiotics currently in clinical development. The PEW Charitable Trust. http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development. Accessed 15 Sept 2015 (published February 2014, updated July 28, 2015).
67. Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996-2005. doi: 10.1056/NEJMoa1411162.
68. Basoli A, Chirletti P, Cirino E, D'Ovidio NG, Doglietto GB, Giglio D, et al. A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs >or=5 days in community-acquired intraabdominal infection. J Gastrointest Surg. 2008;12(3):592-600. doi: 10.1007/s11605-007-0277-x.
69. Hedrick TL, Evans HL, Smith RL, McElearney ST, Schulman AS, Chong TW, et al. Can we define the ideal duration of antibiotic therapy? Surg Infect (Larchmt). 2006;7(5):419-32. doi: 10.1089/sur.2006.7.419.
70. Tellado JM, Sen SS, Caloto MT, Kumar RN, Nocea G. Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain. Scand J Infect Dis. 2007;39(11-12):947-55. doi: 10.1080/00365540701449377.
71. Edelsberg J, Berger A, Schell S, Mallick R, Kuznik A, Oster G. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt). 2008;9(3):335-47. doi: 10.1089/sur.2006.100.
72. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-9. doi: 10.1001/jama.2009.1754.
73. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin. 2011;27(1):19-34. doi: 10.1016/j.ccc.2010.09.006.
74. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840-51. doi: 10.1097/CCM.0b013e3181961bff (quiz 59).
75. Adnan S, Paterson DL, Lipman J, Kumar S, Li J, Rudd M, et al. Pharmacokinetics of beta-lactam antibiotics in patients with intra-abdominal disease: a structured review. Surg Infect (Larchmt). 2012;13(1):9-17. doi: 10.1089/sur.2011.046.
76. Bedikian A, Okamoto MP, Nakahiro RK, Farino J, Heseltine PN, Appleman MD, et al. Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother. 1994;38(1):151-4.
77. Karjagin J, Lefeuvre S, Oselin K, Kipper K, Marchand S, Tikkerberi A, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther. 2008;83(3):452-9. doi: 10.1038/sj.clpt.6100312.
78. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother. 2005;56(2):388-95. doi: 10.1093/jac/dki243.
79. Sartelli M. A focus on intra-abdominal infections. World J Emerg Surg. 2010;5:9. doi: 10.1186/1749-7922-5-9.